Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Australian Journal of General Practice|June 1, 2021
Medical cannabis and drivingThomas R Arkell, Danielle McCartney, Iain S McGregor
Neuroscience and Biobehavioral Reviews|January 26, 2021
Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic reviewDanielle McCartney, Thomas R Arkell, Christopher Irwin, et al.
Journal of Psychopharmacology (Oxford, England)|February 9, 2024
A semi-naturalistic open-label study examining the effect of prescribed medical cannabis use on simulated driving performanceBrooke Manning, Thomas R Arkell, Amie C Hayley, et al.
CNS Drugs|November 9, 2023
A Semi-Naturalistic, Open-Label Trial Examining the Effect of Prescribed Medical Cannabis on Neurocognitive PerformanceThomas R Arkell, Brooke Manning, Luke A Downey, et al.
Addiction Biology|March 1, 2022
Acute effects of amphetamine and related psychostimulants on impulsivity: a systematic review of clinical trialsThomas R Arkell, Kristina Bradshaw, Luke A Downey, et al.
JAMA Network Open|May 9, 2023
Assessment of Medical Cannabis and Health-Related Quality of LifeThomas R Arkell, Luke A Downey, Amie C Hayley, et al.
Neuroscience and Biobehavioral Reviews|November 12, 2021
Are blood and oral fluid Δ9-tetrahydrocannabinol (THC) and metabolite concentrations related to impairment? A meta-regression analysisDanielle McCartney, Thomas R Arkell, Christopher Irwin, et al.
Traffic Injury Prevention|February 5, 2021
The failings of per se limits to detect cannabis-induced driving impairment: Results from a simulated driving studyThomas R Arkell, Tory R Spindle, Richard C Kevin, et al.
Trials|February 7, 2026
Effects of prescribed medical cannabis and alcohol on real-world driving performance (CAN-TRACK): a study protocol for a two-phase trialThomas R Arkell, Amie C Hayley, Blair Aitken, et al.
Journal of Psychopharmacology (Oxford, England)|October 12, 2024
Driving performance and ocular activity following acute administration of 10 mg methylphenidate: A randomised, double-blind, placebo-controlled studyBlair Aitken, Luke A Downey, Serah Rose, et al.
Pageof 3